The global acquired orphan blood diseases therapeutics market size reached US$ 8.8 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 17.2 Billion by 2032, exhibiting a growth rate (CAGR) of 7.5% during 2024-2032. More Info:- https://www.imarcgroup.com/acquired-orphan-blood-diseases-therapeutics-market

1. Global Acquired Orphan
Blood Diseases
Therapeutics Market
Research and Forecast
Report 2024-2032
Format: PDF+EXCEL
© 2023 IMARC All Rights Reserved

2. About IMARC Group
International Market Analysis Research and Consulting Group is a leading adviser on management
strategy and market research worldwide. We partner with clients in all regions and industry
verticals to identify their highest-value opportunities, address their most critical challenges, and
transform their businesses.
IMARC’s information products include major market, scientific, economic and technological
developments for business leaders in pharmaceutical, industrial, and high technology
organizations. Market forecasts and industry analysis for biotechnology, advanced materials,
chemicals, food and beverage, travel and tourism, nanotechnology and novel processing methods
are at the top of the company’s expertise.
IMARC’s tailored approach combines unfathomable insight into the dynamics of companies and
markets with close cooperation at all levels of the client organization. This ensures that our clients
achieve unmatchable competitive advantage, build more proficient organizations, and secure lasting
results.

3. Report Highlight
and Description
According to the latest report by IMARC Group, titled "Acquired Orphan
Blood Diseases Therapeutics Market: Global Industry Trends, Share, Size,
Growth, Opportunity and Forecast 2024-2032," the global acquired orphan
blood diseases therapeutics market size reached US$ 8.8 Billion in 2023.
Acquired orphan blood disease therapeutics refers to the specialized medical
treatments designed for rare blood disorders that are developed post-birth.
They include a range of treatment modalities, such as targeted therapies,
biologics, small molecule inhibitors, and gene therapies. Acquired orphan blood
disease therapeutics are engineered to combat specific aspects of the disorder
by utilizing complex biological components, proteins, or synthetic molecules.
They are employed in hospitals, specialized treatment centers, and research
institutions.
Acquired orphan blood disease therapeutics offer numerous benefits, including
early intervention, personalized treatment plans, improved patient quality of
life, minimized disease progression, and curative possibilities. Additionally,
they offer reduced side effects, targeted drug delivery, quicker recovery, cost-
effectiveness in long-term disease management, and an increased treatment
success rate.
Request for a PDF sample of this report:
https://www.imarcgroup.com/acquired -orphan-blood-diseases-therapeutics-
market/requestsample

4. Report Description
Global Acquired Orphan Blood Diseases Therapeutics Market Trends:
The rapid advancements in medical research contributing to the identification and development of effective and targeted
treatments for acquired orphan blood diseases, are major factors propelling the market growth. Moreover, the
implementation of government policies and incentives, such as exclusive marketing rights and tax credits that encourage
pharmaceutical companies to invest in research and innovation initiatives, is supporting the market growth. Along with
this, the growing awareness and advocacy efforts by patient organizations and healthcare providers to educate the public
and policy-makers about the critical need for treatment is stimulating the market growth. Besides this, rapid advances in
genomic and proteomic technologies leading to the precise identification of disease etiologies are anticipated to drive the
market growth. Furthermore, the rising partnerships and collaborations among research institutions, pharmaceutical
companies, and healthcare providers for sharing knowledge, resources, and financial risks that accelerate the
development and distribution of therapeutics are bolstering the market growth. In addition to this, the increasing
establishment of specialized healthcare facilities and the availability of sk illed professionals that serve to decentralize
treatment, mak ing it more accessible to a broader patient base, is acting as a growth-inducing factor. Apart from this, the
rising prevalence of personalized medicine and the growing focus on patient-centric care models are also favoring the
market growth. In line with this, the sudden shift towards value-based healthcare that impacts reimbursement policies,
mak ing it financially viable for healthcare providers and patients to opt for advanced treatment options, is creating
remunerative growth opportunities f or the market.
View Report TOC, Figures and Tables: https://www.imarcgroup.com/acquired-orphan-blood-diseases-
therapeutics-market

5. Report
Segmentation
Therapy Insights:
• Recombinant Factor
• Immunoglobulin Infusion Therapy
• Activated Prothrombin Complex Concentrate
• Thrombopoietin Receptor Agonists
• Others
Disease Indication Insights:
• Acquired Agranulocytosis
• Acquired Hemophilia
• Acquired Von Willebrand Syndrome
• Paroxysmal Nocturnal Hemoglobinuria (PNH)
• Myelodysplastic Syndrome
• Others

6. Report
Segmentation
Distribution Channel Insights:
• Hospital Pharmacy
• Retail Pharmacy
• Others
Regional Insights:
• North America
• Asia-Pacific
• Europe
• Latin America
• Middle East and Africa

7. Competitive
Landscape with
Key Players
• Alexion Pharmaceuticals Inc. (AstraZeneca plc)
• Amgen Inc.
• GSK plc
• Novartis AG
• Novo Nordisk A/S
• Otsuka Pharmaceutical Co. Ltd.
• Rigel Pharmaceuticals Inc.
• Roche Holding AG
• Sanofi
• Takeda Pharmaceutical Company Limited

8. Key Questions
Answered in
the Report
How has the global acquired orphan blood diseases therapeutics
market performed so far, and how will it perform in the coming
years?
What are the drivers, restraints, and opportunities in the global
acquired orphan blood diseases therapeutics market?
What is the impact of each driver, restraint, and opportunity on the
global acquired orphan blood diseases therapeutics market?
What are the key regional markets?
Which countries represent the most attractive acquired orphan
blood diseases therapeutics market?
What is the breakup of the market based on the therapy?
Which is the most attractive therapy in the acquired orphan blood
diseases therapeutics market?

9. Key Questions
Answered in
the Report
What is the breakup of the market based on the disease indication?
Which is the most attractive disease indication in the acquired
orphan blood diseases therapeutics market?
What is the breakup of the market based on the distribution
channel?
Which is the most attractive distribution channel in the acquired
orphan blood diseases therapeutics market?
What is the competitive structure of the global acquired orphan
blood diseases therapeutics market?
Who are the key players/companies in the global acquired orphan
blood diseases therapeutics market?

10. Table of
Contents
1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 Global Acquired Orphan Blood Diseases Therapeutics
Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 Market Breakup by Therapy
6.1 Recombinant Factor
6.1.1 Mark et Trends
6.1.2 Mark et Forecast
6.2 Immunoglobulin Infusion Therapy
6.2.1 Mark et Trends
6.2.2 Mark et Forecast
6.3 Activated Prothrombin Complex Concentrate
6.3.1 Mark et Trends
6.3.2 Mark et Forecast

11. Table of
Contents
6.4 Thrombopoietin Receptor Agonists
6.4.1 Mark et Trends
6.4.2 Mark et Forecast
6.5 Others
6.5.1 Mark et Trends
6.5.2 Market Forecast
7 Market Breakup by Disease Indication
7.1 Acquired Agranulocytosis
7.1.1 Mark et Trends
7.1.2 Mark et Forecast
7.2 Acquired Hemophilia
7.2.1 Mark et Trends
7.2.2 Mark et Forecast
7.3 Acquired Von W illebrand Syndrome
7.3.1 Market Trends
7.3.2 Mark et Forecast
7.4 Paroxysmal Nocturnal Hemoglobinuria (PNH)
7.4.1 Mark et Trends
7.4.2 Mark et Forecast
7.5 Myelodysplastic Syndrome
7.5.1 Mark et Trends
7.5.2 Mark et Forecast
7.6 Others
7.6.1 Mark et Trends
7.6.2 Mark et Forecast
8 Market Breakup by Distribution Channel
8.1 Hospital Pharmacy
8.1.1 Mark et Trends
8.1.2 Mark et Forecast
For more information, visit :
https://www.imarcgroup.com/acquired -orphan-blood-diseases-
therapeutics-market/toc

12. Disclaimer
© 2023 IMARC All Rights Reserved
This Publication and all it’s contents unless otherwise mentioned are copyrighted in the
name of International Market Analysis Research and Consulting (IMARC). No part of this
publication may be reproduced, repackaged, redistributed or resold in whole or in any part.
The publication may also not be used in any form or by and means graphic electronic or
mechanical, including photocopying, recording, taping or by information storage or retrieval,
or by any other form, without the express consent of International Market Analysis Research
and Consulting (IMARC).
Disclaimer: All contents and data of this publication, including forecasts, data analysis and
opinion have been based on information and sources believed to be accurate and reliable at
the time of publishing. International Market Analysis Research and Consulting makes no
representation of warranty of any kind as to the accuracy or completeness of any Information
provided. IMARC accepts no liability whatsoever for any loss or damage resulting from
opinion, errors or inaccuracies if any found this publication.
IMARC, IMARC Group and Global Therapy Insight Series are registered trademarks of
International Market Analysis Research and Consulting. All other trademarks used in this
publication are registered trademarks of their respective companies.

13. Contact Us
Visit us at :
https://www.imarcgroup.com
TELEPHONE: +1-631-791-1145
E-MAIL: sales@imarcgroup.com